Вы находитесь на странице: 1из 5

. . , . . , . .

,
. . , . .

m`prxemh trmj0hnm`k|mni `jhbmnqh


meipnthknb r deei q `noh)eqjhl depl`hnl
h hu jnppej0h khjnohdnl
j=-!= * ,,*%L ,3% % ,,, = ! % % ,, , =K%!=2%!%L ,= %2,*, toj , ooq
j3K=*% % %3=!2"% % ,,*% % 3,"!,22=

b"  ,


,
.

l 2%,*= , %"=,
150 ,
IgE- ,
, .
46 6
9 IgE-
, 2 ,

: 1-
31 ,
, 2- 15 ,

. 30
.
: ,
, ( ) , -
.
30 1 2 5 , 1 1
15 ( 25 ).
,
SCORAD, -
: , (2004),
,

,
.
6 , /, /, , , ( ) 0
3 : 0 , 1 ,
2 , 3 .

(
9%, - 18%, 9%,
18%,
1%).
(, ) 0 10.
SCORAD : = /5
+ 7/2 + , : , ,
. , c IgE-

( 23%
), ( 19%), (
10,8%), ( 19%) ( 8 2 )
47%, (10,8%), (4,8%),
(4,8%).
. 2 :

616-002-092:612.112.92.06:577.175.85(048.8)


,
[5], () [17, 3, 16].
:

[2,
16].

CD4- - [15, 19].

,

. , ,
() [4, 1],
,
, IgE,
in vitro .

,
.

113

.
,
SCORAD, ()
25,332,38%, ()
8,400,52 .
(), , 7,400,91 . SCORAD 41,862,56 .


.


[12]:
( FACScan,
) (CD11b(+)-, CD16(+)-, CD25(+),CD95(+)-), ,
NBT-. St. aureus ( 209),
( %), ()
(), (%)
().
(),
(%) () c NBT-.
Microsoft Excel STATISTICA 6.0.

p 3%2=2/ , %"=,
,
( 1,5 ) : 3,090,17 2,721,77, -

114

.
, (CD11b+)
(CD16+), IgE-
(CD11b(+) 12,570,86
27,311,34; CD16(+) 15,460,85 27,931,79),
(CD11b(+)
0,380,02 0,660,06; CD16(+) 0,400,02
0,710,08). , ,
CD25(+)-
( 12,000,86 20,151,54)
( 0,370,01 0,520,05),
CD95(+)-
10,000,97 24,192,76; 0,240,02 0,480,07 .
,
IgE-
% ( 62,003,06 46,551,70), (
2,870,02 2,170,12) ( 6,350,42 4,640,17)
% 67,23,01 47,681,94 (<0,001),
2,38 ( 2,52+0,01 1,06+0,27).
,

( 0,250,01 2,250,48) 5,3
( 0,320,09 1,710,16)

. % ( 11,60,52 7,551,27), ( 17,50,52 10,041,91) NBT- (<0,01)

, .
1
,
CD16(+)- ( 27,931,79 19,50,65%) CD95(+)-
( 17,51,17 10,501,06) (>0,05),
CD11b(+)- CD25(+)-
().

. 1.
IgE- :
, ,
+ , .

( 38,481,80 48,802,50) ( 2,721,77 3,13 0,23)


CD11b(+)- 27,311,34
16,411,08, CD16(+)- 27,931,79
18,901,13, CD25(+)- 20,151,54 15,510,93,
CD95(+)- 24,192,76 10,501,06,
, 25% .

,

. , % 46,551,70
59,31,03%
(% 47,681,94 65,41,13,
1,06+0,27 2,660,15).


.
,
. ,
, ,
.
(<0,05) (0,750,15
1,510,02 ), (1,340,13) ,
,
(1,630,09).

(),

1 () 3,5
( 1,8 ), 2- 3 (
), 40% .

() ,
( 3,6 , 8,4 2 ). ( ) 1-

( 37 ),
( 6,3 ), 85% 1-

.
SCORAD 1-
4,2 ( 1 ) 14 ( 2 ),
2- 2,5
4,4 .
,
IgE-
- .

nK3 ,
,
, IgE-


, . ,


IgE-
(, )
1-
(+)

2-
()

25,332,38

24,032,76

1 .

7,081,06 <0,01

13,072,33

2 .

2,550,57 <0,01

7,561,72

8,400,52

8,000,54

1 .

2,300,21 <0,02

3,400,35

2 .

1,000,14 <0,02

1,660,19

7,400,91

7,530,91

1 .

0,200,09 <0,001

1,200,22

2 .

41,862,56 <0,01

40,442,11

1 .

9,680,87 <0,01

15,591,41

2 .

3,360,70 <0,01

8,560,95

(%) (
)

()
(
)

()
( )

SCORAD ()

0,200,16

115

, ,
, ,

.
,
(CD25+,
CD95+), [6]
.

CD25(+)- ,
-2, . , ,
, ,
, , , ,
, , [9].
- ,
,
- [14, 7, 8, 10, 13],
, , , , DR- HLA, -, -1,
, () ,
.
,

IgE- , ,
-
, , ,

IgE-
, ,

.
15.05.2008

116

1. . . . : ,1988. 192 .
2. . ., . ., . . // , 1995. 2. . 1620.

3. . ., . ., . ., . .
// . 2004. 4. . 5861.
4. . . // . .1- . .
, . 1997. . 1925.
5. . . ? // .
. 2004. 1. . 3741.
6. . ., . . //
. ., 2004. . 8. 2.
. 125135.
7. . ., . ., . .,
. . // .
1999. 6. . 6061.
8. . ., . ., . ., . . - ,
// , . 2, 2003.
. 3036.
9. . ., . ., . . .

// . . -. . , 1994.
. 3435.
10. , . ., . .,
. ., . .

// .. ,
, 2004 // Rus. Journ. of Immunology. 2004. V. 9. S. 1.
P. 132.
11. -
: , .
., 2004.
12. . ., . ., . .

: . ,
, , 1996, 96/11. 25 .
13. . . : . . . . , , 2006.
23 .
14. . ., . ., . .
//
. ., 2005. . 1936.
15. . .
// . . 2007. 1. . 519.
16. . ., . ., . . . .
: . , 1997.
. 6.
17. . ., . . : // . . .:
, 2002. 192 .
18. Lederer E. Natural and synthetic immunomodulators derived
from the mycobacterial cell wall // Advances in Immunomod., 1988.
P. 936.
19. Pulendran B., Cumar P., Kutler C. et all Lipopolysacharides
from distingt pathogens induct different classes of immune responses
in vivo // J. Immunology., 2001. V. 167. . 50675076.

N. V. KOLESNIKOVA, . . KOKOV,
L. N. KOKOVA, G. A. CHUDILOVA,
T. M. ANDRONOVA
DISTURBANSES OF THE FUNCTIONAL
ACTIVITY OF NEUTROPHILS IN CHILDREN
WITH ATOPIC DERMATITIS AND THEIR
CORRECTION OF LICOPID
In this paper we are analysed results of the
researches of clinical and immunomodulations effects

of new Russian peptid immunomodulator Likopid


in regard to functional activity of neutrophilic
granulocytes (NG) of peripheral blood of children
with atopic dermatitis.
Possible reasons of the looked after positive
immunomodulation effects of Likopid are analysed
and expedience of its application is grounded
at the defects of basic functions (by a receptor,
macrophageal bactericidal systems) of neutrophils
together with allergic IgE-mediated diseases
immunological effect.

. .

b{anp nohl`k|mni `jhjh n0emjh


hmp`m``k|mncn qnqnmh oknd` oph p`gbhbxeiq
dhqjnnpdhm`0hh pndnbni deek|mnqh
j=-!= =*3&!2"= , ,*% % ,, toj , ooq
j3K=*% % %3=!2"% % ,,*% % 3,"!,22=
.

l 2%,*= , %"=,
,
- ( ),
. , ,
,
- 20002007 ., ,
: 2000 . 10%, 2001 . 7%, 2002 . 8%,
2003 . 11%, 2004 . 10%, 2005 . 10%,
2006 . 8%, 2007 . 8% (9 0,4%).
-
200 . 26,45
9,46 . 36 2,5 .
;
. .
, 2003.
150
. 100 :
50 (I ), 50
2 (II ), 50 (III ); 50
(IV ). , 3 ( ) 1 .

: 5
300 : ; 1
1015 10 ;
8 / (40 ).
150
. 100 :

618.5 06:618.46 008 073.432.19


.
,
[6, 7, 14].
[11], , --
, ,
3

[12, 15, 16].

,
,
/
[3, 4, 12], , [8,
14].

[2, 3, 4, 12]
, -- [13].
-
.
; ,
.

117